Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching Any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL®) in Patients With Schizophrenia

NCT00234377 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00234377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00234377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching Any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL®) in Patients With Schizophrenia
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2004
Completion date
May 31, 2006
Enrollment
550
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia